Professor Guarantees Safety of COVID-19 Vaccine Clinical Trials
Translator
Ricky Mohammad Nugraha
Editor
Laila Afifa
Selasa, 3 November 2020 18:31 WIB
TEMPO.CO, Jakarta - Head of the COVID-19 vaccine clinical trial research team at Bandung’s Padjadjaran University, Professor Dr. Kusnandi Rusmil, assured the Sinovac vaccine trials his team is handling is considered to be the safest compared to other vaccine trial researches.
“This is not my first time handling a clinical trial, honestly it has been 30 times and this one is considered so far to be safe,” said Kusnandi in a virtual discussion on November 3. “Compared to tetanus and diphtheria vaccine trials, this is much safer.”
He explained that the Sinovac vaccine phase one and two trials had already taken place in China, along with its preclinical trials before involving human test subjects. Kusnandi Rusmil said that lab test animals subjected to the vaccinations did not show significant changes to their liver, spleen, lungs, intestines.
The Sinovac COVID-19 vaccine trials had involved 1,620 volunteers in its first phase while the second clinical trials will be given to 1,590 volunteers. He said there were no significant side effects on the human volunteers throughout the first phase.
Read: Vaccinologist Reveals Success Story of Vaccines Against Pandemic
FRISKI RIANA
